Treatment of heart disease by disruption of the anchoring of pp2a
AssigneesUniversity of Miami, The Board of Trustees of the Leland Stanford Junior University
InventorsMichael KAPILOFF, Jinliang LI
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAPβ. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAPβ to which PP2A binds.
Claims28
A method of treating or preventing heart failure with reduced ejection fraction, comprising administering to cardiac cells of a patient a composition that maintains a level of phosphorylation on serum response factor (SRF).
A composition that encodes a molecule that inhibits the anchoring of PP2A to mAKAP.
A composition comprising a vector that encodes a molecule that inhibits the anchoring of PP2A to mAKAP.
Dependencies are inferred from the claim text.